Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg have been found in the United States. The FDA ...

Novo Nordisk already has broad FDA approvals ... 2 diabetes who also have atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD). It would become the first add-on ...

Novo Nordisk on Saturday said its diabetes ... average in patients with diabetes and established heart disease, with or without chronic kidney disease. The Danish drugmaker presented the results ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...

Novo Nordisk (NVO ... events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).” Discover the latest stocks recommended by top Wall Street ...

Novo Nordisk A/S NVO on Saturday presented ... events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD). The SOUL trial achieved its primary ...